Celltrion, Inc., together with its subsidiaries, develops and produces therapeutics based on proteins including oncology treatment drugs in South Korea. The company markets Remsima, Truxima, and Herzuma products; generic pharmaceuticals; covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 for the treatment of asthma and urticaria that is in phase 1 clinical trial; CT-P17 for the treatment of rheumatoid arthritis, psoriatic arthritis, and IBD, which is in phase 3 clinical trial; CT-P16 for the treatment of metastatic colorectal cancer and breast cancer that is in phase 3 clinical trial; CT-P41 for the treatment of osteoporosis and bone loss, which is in phase 1 clinical trial; CT-P43 for the treatment of psoriasis, crohn's disease, and ulcerative colitis that is in phase 3 clinical trial; CT-P42 for the treatment of diabetic macular edema, which is in phase 3 clinical trial; CT-P27 for the treatment of pandemic/seasonal influenza that is in phase 2 clinical trial; CT-P59 for the treatment of COVID-19, which is in phase 3 clinical trial; and CT-G20 for the treatment of Cardiomyopathy that is in phase 1 clinical trial. Celltrion, Inc. has a partnership with Inhalon Biopharma, Inc. to develop IN-006, an inhaled form of regdanvimab for treating patients with COVID-19. The company was founded in 2002 and is headquartered in Incheon, South Korea.
Stock split history for Celltrion, Inc. (068270.KS)
Celltrion, Inc. stock (symbol: 068270.KS) underwent a total of 13 stock splits.
The most recent stock split occured on Dec 28, 2022.
Annual Revenue
| Date | Splite | Multiple |
|---|---|---|
| 2022-12-28 | 1.04:1 | 1.04 |
| 2021-12-29 | 1.02:1 | 1.02 |
| 2020-12-29 | 1.02:1 | 1.02 |
| 2019-12-27 | 1.05:1 | 1.05 |
| 2018-12-27 | 1.02:1 | 1.02 |
| 2017-12-27 | 1.02:1 | 1.02 |
| 2016-12-28 | 1.05:1 | 1.05 |
| 2015-12-29 | 1.03:1 | 1.03 |
| 2014-12-29 | 1.05:1 | 1.05 |
| 2013-12-27 | 1.03:1 | 1.03 |
| 2013-03-04 | 1:2 | 1 |
| 2012-12-27 | 1.15:1 | 1.15 |
| 2012-05-24 | 1.5:1 | 1.5 |